CYP2J5 Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-10137
Key Product Details
Species Reactivity
Mouse
Applications
Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit
Concentration
0.5 mg/ml
Product Specifications
Immunogen
The immunogen is a synthetic peptide directed towards the middle terminal region of mouse CYP2J5 (NP_034137.1). Peptide sequence GPHQKIFRNWGKLKLFVSHIVKKHEKDWNPDEPRDFIDAFLIEMQKDPDR
Clonality
Polyclonal
Host
Rabbit
Theoretical MW
58 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Scientific Data Images for CYP2J5 Antibody
Western Blot: CYP2J5 Antibody [NBP3-10137]
Western Blot: CYP2J5 Antibody [NBP3-10137] - Western blot analysis of CYP2J5 in Mouse Heart lysates. Antibody dilution at 1ug/mlApplications for CYP2J5 Antibody
Application
Recommended Usage
Western Blot
1.0 ug/ml
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS, 2% Sucrose
Preservative
0.09% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: CYP2J5
Alternate Names
Arachidonic acid epoxygenase, Cyp2j5, CYPIIJ5, Cytochrome P450 2J5, EC=1.14.14.1, Uncharacterized protein
Gene Symbol
Cyp2j5
Additional CYP2J5 Products
Product Specific Notices for CYP2J5 Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...